Voices of Biotech
Podcast: MilliporeSigma says education vital to creating unbreakable chain for sustainability
MilliporeSigma discusses the importance of people, education, and the benefits of embracing discomfort to bolster sustainability efforts.
August 27, 2021
Sponsored by Thermo Fisher Scientific
Chimeric antigen receptor (CAR) T cell therapies have advanced rapidly in recent years, with a number of targets in clinical research and several US Food and Drug Administration (FDA)-approved products already on the market. There has been tremendous effort to make CAR T cells more effective, safe, and persistent when treating patients. On the manufacturing side, however, errors, lot-to-lot variation, and contamination can be associated with open processes and manual handling of CAR T cells.
Cell isolation, gene editing, expansion, and cryopreservation are complex steps in a typical autologous CAR T cell manufacturing process. Integrating this complicated multistep workflow into a closed, modular, benchtop system can facilitate transitions from laboratory scale to clinical manufacturing and improve a CAR T cell product’s consistency, purity, and safety. Thermo Fisher Scientific presents a digitally compatible, good manufacturing practice (GMP)-compliant, semiautomated manufacturing platform, which when used with Gibco™ CTS™ reagents, protocols, and analytics can result in consistent, efficacious CAR T cell production.
Figure 1: (top) CAR T cell therapy workflow; (bottom) workflow solutions from Thermo Fisher Scientific
Fill out the form below to read the complete white paper now.
You May Also Like